Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Dianthus Therapeutics, Inc.

< Previous 1 2 Next >
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Participate in Four Investor Conferences During November
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
News headline image
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
Tickers DNTH
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.